| Literature DB >> 36199104 |
Hong-Xi Zhao1, Xia Li2, Jun-Long Liu3, Gui-Quan Guan3, Xin-Gang Dan4.
Abstract
BACKGROUND: When Theileria annulata infects host cells, it undertakes unlimited proliferation as tumor cells. Although the transformed cells will recover their limited reproductive characteristics and enter the apoptosis process after treatment with buparvaquone (BW720c), the metabolites and metabolic pathways involved are not clear.Entities:
Keywords: Buparvaquone (BW720c); Metabolomics; Pathway; Theileria annulata
Mesh:
Substances:
Year: 2022 PMID: 36199104 PMCID: PMC9533618 DOI: 10.1186/s13071-022-05450-0
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 4.047
Fig. 1PCA scatter plots of the buparvaquone group and DMSO group. a–c Drug treatment at 24 h, 48 h, and 72 h, respectively (neg). d–f Drug treatment at 24 h, 48 h, and 72 h, respectively (pos). The x-axis represents PC1, the y-axis represents PC2. Symbols: BB, BC, and BD represent 24 h, 48 h, and 72 h of BW720c treatment, respectively; CB, CC, and CD represent 24 h, 48 h, and 72 h of DMSO treatment, respectively. The numbers 1–6 at the end of each string represent the samples in each group
Fig. 2OPLS-DA scoring diagrams of the buparvaquone group and DMSO group. a–c 24 h, 48 h, and 72 h (neg); d–f 24 h, 48 h, and 72 h (pos). 24 h (R2X = 0.759, R2Y = 0.993, Q2 = 0.664 [neg]; R2X = 0.531, R2Y = 0.99, Q2 = 0.603 [pos]). 48 h (R2X = 0.43, R2Y = 0.992, Q2 = 0.837 [neg]; R2X = 0.435, R2Y = 0.995, Q2 = 0.82 ([pos]). 72 h (R2X = 0.471, R2Y = 0.992, Q2 = 0.933 [neg]; R2X = 0.552, R2Y = 0.999, Q2 = 0.92 [pos]). The x-axis represents t1, y-axis represents to 1. Symbol system: BB, BC, and BD represent 24 h, 48 h, and 72 h of BW720c treatment, respectively; CB, CC, and CD represent 24 h, 48 h, and 72 h of DMSO treatment, respectively. The numbers 1–6 at the end of the string are the number of samples in each group
Statistics of Q2 value of OPLS-DA under BW720c and control (DMSO) treatments
| 24 h | 48 h | 72 h | |
|---|---|---|---|
| neg | 0.664 | 0.837 | 0.933 |
| pos | 0.603 | 0.820 | 0.920 |
Fig. 3Permutation tests of the OPLS-DA model. a, b 48 h and 72 h (neg); c, d 48 h and 72 h (pos). 48 h (pR2Y = 0.01, pQ2 = 0.01 (neg); pR2Y = 0.01, pQ2 = 0.01 [pos]); 72 h (pR2Y = 0.01, pQ2 = 0.01 (neg); pR2Y = 0.005, pQ2 = 0.005 [pos])
Common differential metabolites at 48 h and 72 h in both modes
| Model | ID | Metabolite | Regulated | KEGG annotation |
|---|---|---|---|---|
| neg | meta_3 | Dimethylformamide | Up | 0 |
| meta_17 | Up | 15 | ||
| meta_22 | Hypotaurine | Up | 2 | |
| meta_34 | Up | 10 | ||
| meta_36 | Tyramine | Up | 3 | |
| meta_38 | Purine | Up | 0 | |
| meta_41 | Picolinic acid | Down | 2 | |
| meta_51 | Up | 11 | ||
| meta_56 | Up | 1 | ||
| meta_78 | Up | 17 | ||
| meta_99 | Tryptamine | Up | 3 | |
| meta_102 | Down | 1 | ||
| meta_109 | Up | 10 | ||
| meta_120 | Pro-Gly | Up | 0 | |
| meta_133 | Up | 19 | ||
| meta_146 | DL-Indole-3-lactic acid | Up | 0 | |
| meta_181 | Up | 12 | ||
| meta_186 | Methylthiouracil | Up | 0 | |
| meta_251 | Meteloidine | Down | 0 | |
| meta_252 | Tyrosyl-Glycine | Up | 0 | |
| meta_253 | Tyr-Gly | Up | 0 | |
| meta_261 | Up | 0 | ||
| meta_271 | Pro-Glu | Up | 0 | |
| meta_275 | 2-Methylbutyroylcarnitine | Down | 0 | |
| meta_280 | 2,6-Diamino-4-hydroxy-5- | Down | 0 | |
| meta_319 | 1-Amino-3-hydroxymethyl-5-methyl-adamantane | Up | 0 | |
| meta_324 | Primaquine | Up | 0 | |
| meta_343 | 1-Chloro-2,2-bis(4′-chlorophenyl)ethylene | Up | 0 | |
| meta_425 | Phe-Glu | Up | 0 | |
| meta_459 | Xanthosine | Down | 3 | |
| meta_475 | Flusilazole | Down | 0 | |
| meta_481 | Arg-Thr | Up | 0 | |
| meta_502 | Norelgestromin | Up | 0 | |
| meta_503 | Oxprenolol | Up | 0 | |
| meta_520 | Triflupromazine | Up | 0 | |
| meta_543 | Adenosine monophosphate | Down | 0 | |
| meta_545 | Butote | Up | 0 | |
| meta_589 | 4,7,10,13,1 6,19-Docosahexaenoic acid | Up | 0 | |
| meta_597 | 1,2- | Up | 0 | |
| meta_653 | 4-Hydroxyphenylacetonitrile triacetylrhamnoside | Up | 0 | |
| meta_671 | Tryprostatin A | Up | 0 | |
| meta_674 | Pro-Ser | Up | 0 | |
| meta_690 | Abiraterone sulfate | Up | 0 | |
| meta_706 | Down | 0 | ||
| meta_740 | Retinyl beta-glucuronide | Up | 0 | |
| meta_770 | 1- | Down | 0 | |
| meta_808 | 1- | Down | 0 | |
| meta_816 | Nb-trans-Feruloylserotonin glucoside | Up | 0 | |
| meta_873 | Ile-Phe | Up | 0 | |
| meta_877 | Nb-trans-Feruloylserotonin glucoside | Up | 0 | |
| meta_962 | Quercetin 7-glucuronide 3-rhamnoside | Up | 0 | |
| meta_1032 | Norbadione A | Down | 0 | |
| meta_1113 | Torvoside E | Up | 0 | |
| meta_1139 | Phyllanthusol B | Up | 0 | |
| meta_1154 | PC[18:2(9Z,12Z)/20:1(11Z)] | Up | – | |
| pos | meta_10 | 3-Hydroxyisovaleric acid | Down | 0 |
| meta_11 | Ethylenethiourea | Down | 0 | |
| meta_38 | Up | 10 | ||
| meta_39 | Purine | Up | 0 | |
| meta_53 | Up | 11 | ||
| meta_54 | Up | 7 | ||
| meta_57 | Up | 1 | ||
| meta_77 | Up | 16 | ||
| meta_81 | Methyl 4-(methylthio)butyrate | Up | 0 | |
| meta_82 | Up | 8 | ||
| meta_93 | Orotate | Up | 2 | |
| meta_96 | Up | 2 | ||
| meta_101 | 2-Oxoadipic acid | Up | 6 | |
| meta_111 | Phenylpyruvate | Up | 5 | |
| meta_126 | Cytosine | Up | 2 | |
| meta_139 | Up | 3 | ||
| meta_145 | Aspirin | Up | 1 | |
| meta_148 | Up | 19 | ||
| meta_177 | 1-Isothiocyanato-4-phenylbutane | Up | 0 | |
| meta_185 | Dihydrolipoate | Down | – | |
| meta_208 | Up | 12 | ||
| meta_219 | Down | 6 | ||
| meta_220 | Benzyl Benzoate | Up | 0 | |
| meta_234 | 2-Iodophenol | Up | 0 | |
| meta_238 | Pseudoecgonine | Up | 0 | |
| meta_278 | 1-(2,4,5-Trimethoxyphenyl)-1,2-propanedione | Up | 0 | |
| meta_287 | Methasulfocarb | Up | 0 | |
| meta_299 | Down | 4 | ||
| meta_308 | (E)-2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide | Up | 0 | |
| meta_332 | 3-methylcytidine | Down | 0 | |
| meta_339 | Primaquine | Up | 0 | |
| meta_344 | Carbadox | Up | 0 | |
| meta_377 | Up | 0 | ||
| meta_394 | 2-Iodophenol | Up | 0 | |
| meta_408 | Xanthosine | Down | 3 | |
| meta_460 | Malathion monocarboxylic acid | Up | 0 | |
| meta_464 | Eicosapentaenoic Acid | Up | 1 | |
| meta_467 | Hesperetin | Up | 0 | |
| meta_498 | Hippeastrine | Down | 0 | |
| meta_509 | Adipostatin A | Up | 0 | |
| meta_523 | Down | 0 | ||
| meta_528 | (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,1 6,19-Docosahexaenoic acid | Up | 0 | |
| meta_533 | (7Z,10Z,13Z,16Z,19Z)-Docosapentaenoic acid | Up | 0 | |
| meta_536 | Adrenic acid | Up | 1 | |
| meta_537 | Up | 0 | ||
| meta_538 | 2-Methyl-1,4-naphthalenediol bis(dihydrogen phosphate) | Up | 0 | |
| meta_543 | Cappariloside A | Up | 0 | |
| meta_545 | Docosatrienoic Acid | Up | 0 | |
| meta_551 | Versicolorin A | Up | 0 | |
| meta_610 | Pyriminobac-methyl | Up | 0 | |
| meta_617 | 9-Aminocamptothecin | Up | 0 | |
| meta_657 | Pioglitazone | Down | 0 | |
| meta_660 | Salbutamol 4- | Up | 0 | |
| meta_672 | Methylsyringin | Up | 0 | |
| meta_690 | Shanzhiside | Up | 0 | |
| meta_731 | Azidocillin | Up | 0 | |
| meta_750 | Benzbromarone | Up | 0 | |
| meta_763 | 3- | Up | 0 | |
| meta_778 | Phosacetim | Up | 0 | |
| meta_785 | Margrapine A | Up | 0 | |
| meta_806 | CDP-ethanolamine | Up | 2 | |
| meta_807 | Mollicellin E | Up | 0 | |
| meta_982 | Apramycin | Up | 0 | |
| meta_1107 | Dimoracin | Up | 0 | |
| meta_1113 | Lanceotoxin A | Up | 0 | |
| meta_1115 | Isotetrandrine | Up | 0 | |
| meta_1120 | Geranyl diphosphate | Up | 3 | |
| meta_1154 | Up | 0 | ||
| meta_1168 | Streptomycin 6-phosphate | Up | 0 | |
| meta_1215 | Adouetine Z | Up | 0 | |
| meta_1230 | PE(P-18:0/14:0) | Down | 0 | |
| meta_1239 | PE[P-18:1(9Z)/16:1(9Z)] | Up | 0 | |
| meta_1265 | PE[P-18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)] | Up | 0 | |
| meta_1296 | PE[22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:1(11Z)] | Up | 0 | |
| meta_1327 | Quinquenoside F1 | Up | 0 | |
| meta_1332 | Punigluconin | Up | 0 | |
| meta_1376 | Elatoside E | Up | 0 | |
| meta_1377 | PI[20:3(8Z,11Z,14Z)/18:2(9Z,12Z)] | Up | 0 | |
| meta_1388 | Bacteriochlorophyll b | Up | 0 |
Selection is based on an MS2 score greater than 0.75
Fig. 4Metabolite differences in buparvaquone and DMSO treatments. a, b 48 h and 72 h (neg); c, d 48 h and 72 h (pos). The green dots represent the downregulated differential expression metabolites, the red dots represent the upregulated differential expression metabolites, and the black dots represent detected but nonsignificant metabolites. In neg ion mode, 2850 metabolites were found and 2596 metabolites were found in pos ion mode
Fig. 5Cluster analysis of differential metabolites in T. annulata-transformed cells treated with DMSO and buparvaquone. a, b 48 h and 72 h (neg); c, d 48 h and 72 h (pos). log2 conversion and normalization were carried out for cluster analysis
Fig. 6KEGG enrichment analysis of metabolites in host cells after buparvaquone treatment (DMSO is the control treatment group). a, b Metabolic differences at 48 h and 72 h in negative ion mode. c, d Metabolic differences at 48 h and 72 h in positive ion mode. The size of the midpoint in the figure represents the number of significantly different metabolites enriched in the corresponding pathway. The color of the point is related to the Q-value. The abscissa represents the enrichment factor and the ordinate represents the metabolic pathway
Enrichment factor, Q-value and differential metabolite for each metabolic pathway at 48 h and 72 h for both pos and neg modes
| Time | Number | Metabolic pathway | Enrichment factor | Differential metabolite | |
|---|---|---|---|---|---|
| 48 h (neg) | 1 | Valine, leucine, and isoleucine biosynthesis | 4.03 | 0.22 | 4 |
| 2 | 2-Oxocarboxylic acid metabolism | 2.30 | 0.55 | 8 | |
| 3 | Mineral absorption | 2.68 | 0.55 | 6 | |
| 4 | Protein digestion and absorption | 2.15 | 0.93 | 8 | |
| 72 h (neg) | 1 | Mineral absorption | 3.05 | 0.02 | 8 |
| 2 | Aminoacyl-tRNA biosynthesis | 2.45 | 0.07 | 10 | |
| 3 | Protein digestion and absorption | 2.29 | 0.16 | 10 | |
| 48 h (pos) | 1 | Mineral absorption | 3.22 | 0.07 | 7 |
| 2 | Aminoacyl-tRNA biosynthesis | 2.45 | 0.35 | 8 | |
| 3 | Protein digestion and absorption | 2.30 | 0.36 | 9 | |
| 72 h (pos) | 1 | Mineral absorption | 2.74 | 0.24 | 7 |